Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$655K Buy
1,862
+431
+30% +$148K 0.03% 285
2026
Q1
$468K Hold
1,431
0.02% 298
2025
Q4
$468K Buy
1,431
+67
+5% +$21.3K 0.02% 304
2025
Q3
$385K Buy
1,364
+110
+9% +$31.9K 0.02% 316
2025
Q2
$350K Buy
1,254
+217
+21% +$61.5K 0.02% 312
2025
Q1
$323K Buy
1,037
+69
+7% +$20.4K 0.02% 282
2024
Q4
$252K Buy
+968
New +$287K 0.02% 290
2024
Q3
Sell
-655
Closed -$205K 293
2024
Q2
$205K Buy
+655
New +$192K 0.02% 262
2023
Q2
Sell
-1,156
Closed -$279K 177
2023
Q1
$279K Buy
1,156
+2
+0.2% +$491 0.06% 142
2022
Q4
$303K Sell
1,154
-331
-22% -$88.7K 0.07% 132
2022
Q3
$335K Sell
1,485
-145
-9% -$35.1K 0.09% 123
2022
Q2
$396K Buy
1,630
+2
+0.1% +$490 0.1% 118
2022
Q1
$394K Buy
1,628
+1
+0.1% +$230 0.1% 119
2021
Q4
$366K Buy
+1,627
New +$343K 0.08% 136

Other funds holding AMGN

Sax Wealth Advisors's AMGN Position: Q2 2026 in Review

Sax Wealth Advisors increased its Amgen (AMGN) stake by 30% in Q2 2026, buying an estimated $148K and bringing the position to 1,862 shares worth $655K. The position accounts for 0.03% of the portfolio, ranked #285.

Sax Wealth Advisors first reported a position in AMGN in Q4 2021 and has held it in 14 quarters since. 1,289 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Sax Wealth Advisors held 1,862 shares of Amgen worth $655K as of Q2 2026.
  • Sax Wealth Advisors bought 431 Amgen shares in Q2 2026, an estimated $148K.
  • Amgen made up 0.03% of Sax Wealth Advisors's portfolio in Q2 2026, its #285 holding.
  • Sax Wealth Advisors first reported a position in Amgen in Q4 2021 and has held it in 14 quarters since.
  • 1,289 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Sax Wealth Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.